comprehensive -WSS

comprehensive

author：fashion 2025-09-14 08:28:56 - browse：74982

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

WSS

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Ebola: Gilead Sciences antiviral shows promise as new treatment

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

EPA limits use of carcinogenic gas for sterilizing medical devices

First Opinion Podcast: Long Covid needs a new approach

Medicare reduced heart disease by changing how it pays doctors

leisure time

comprehensive

focus

23andMe had bad news about my health. I wish a person had delivered it

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Summit: Biotech founders on deal

In Memoriam: Notable people who died in 2023

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Sports medicine is finally prioritizing gender equality

How many hemophilia patients actually want gene therapy?

Sports medicine is finally prioritizing gender equality

Pushing for an NIH office for post

hotspot

UnitedHealth’s board chair also owns a personal investment firm

STAT Readout Newsletter: Today's biggest biotech updates

Senate committee scrutinizes Medicare Advantage brokers

As AI in medicine takes off, can 'human in the loop' prevent harm?

The EU Joint Clinical Assessment needs to live up to its promise

UCLA team creates talking throat patch for voice disorders

explore

leisure time

explore

leisure time